DAC-002

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameDAC-002
Drug Alias NameDAC-002JS-108DAC-002/JS108
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Tub196 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionTubulin inhibitorsAnti-Trop-2
TargetsTumor-associated calcium signal transducer 2Tubulin
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Dac Biotech Company Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHangzhou Dac Biotech Company Ltd
Inactive CompaniesShanghai Junshi Biosciences Co Ltd
Active IndicationsSmall Cell Lung CarcinomaTriple Negative Breast Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A